<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Target INR for mechanical valves</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Target INR for mechanical valves</h1>
<div class="graphic"><div class="figure"><div class="ttl">Target INR for mechanical valves</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="highlight_gray_text"><strong>Valve position</strong></td> <td class="highlight_gray_text"><strong>Valve type</strong></td> <td class="highlight_gray_text"><strong>Examples</strong></td> <td class="highlight_gray_text"><strong>INR target in patients WITHOUT additional risk factors</strong></td> <td class="highlight_gray_text"><strong>INR target in patients WITH any of the following risk factors:</strong> <ul> <li>Prior thromboembolism</li> <li>Atrial fibrillation</li> <li>Rheumatic mitral stenosis (any degree)</li> <li>LVEF &lt;35%</li> </ul> </td> <td class="highlight_gray_text"><strong>Concurrent aspirin therapy?</strong></td> </tr> <tr> <td class="divider_bottom" rowspan="3">Aortic or pulmonic</td> <td>On-X valve</td> <td>Â </td> <td>2.5 for first 3 months; thereafter 1.5 to 2.0</td> <td>2.5</td> <td>Yes, aspirin 75 to 100 mg orally once daily*</td> </tr> <tr> <td>Low-risk valves</td> <td> <ul> <li>Bileaflet valves</li> <li>Medtronic Hall tilting disc valve</li> </ul> </td> <td>2.5</td> <td>3.0</td> <td>Not routinely*</td> </tr> <tr class="divider_bottom"> <td>High-risk valves</td> <td> <ul> <li>Tilting disc valves other than Medtronic Hall</li> <li>Ball-in-cage</li> </ul> </td> <td>3.0</td> <td>3.5</td> <td>Not routinely*</td> </tr> <tr> <td rowspan="2">Mitral or tricuspid</td> <td>Low-risk valves</td> <td> <ul> <li>Bileaflet valves</li> <li>Medtronic Hall tilting disc valve</li> </ul> </td> <td>3.0</td> <td>3.0</td> <td>Not routinely*</td> </tr> <tr> <td>High-risk valves</td> <td> <ul> <li>Tilting disc valves other than Medtronic Hall</li> <li>Ball-in-cage</li> </ul> </td> <td>3.5</td> <td>3.5</td> <td>Not routinely*</td> </tr> </tbody></table></div><div class="graphic_lgnd">Patients with mechanical valves require anticoagulation with a VKA (eg, warfarin). The approach described here follows the convention in the 2020 American College of Cardiology/American Heart Association (ACC/AHA) and 2021 European Society of Cardiology (ESC) valve guidelines, which specify INR targets rather than ranges. The acceptable range extends to 0.5 INR units on each side of the target. The use of targets was deemed preferable to ranges because it is more likely to reduce the time the INRs are closer to the upper or lower limit of the range. For a patient with more than one mechanical valve, the highest applicable target INR is used.<br/>
	
	Careful INR monitoring is essential. Frequent monitoring is required when establishing the VKA dose, when there is an intercurrent illness or a potentially interacting exposure (such as change in medication or diet), and when the INR is outside the target range. When the patient is on a stable maintenance VKA dose with established therapeutic INR level, the INR is assessed at least monthly in patients with mechanical valves (and at least twice per month in patients with an On-X aortic valve treated with a target INR of 1.5 to 2.0 plus low-dose aspirin).</div><div class="graphic_footnotes">INR: international normalized ratio; 
	LVEF: left ventricular ejection fraction; 
	VKA: vitamin K antagonist.<br/>
	
	* Routine addition of low-dose aspirin is generally not required (except for patients with an On-X aortic valve). For patients with mechanical valves with a concurrent indication for antiplatelet therapy, a decision on whether to add antiplatelet therapy to anticoagulant therapy is based upon assessment of the estimated benefits (eg, reducing risk of coronary stent thrombosis) and risks (eg, bleeding) of such therapy. Refer to UpToDate content on coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy.</div><div class="graphic_reference">Prepared with data from:
	<ol>
<li>Otto CM, Nishimura RA, Bonow RO, et al. 2020
		ACC/AHA guideline for the management of patients with valvular heart disease: A
		report of the American College of Cardiology/American Heart Association Joint
		Committee on Clinical Practice Guidelines. Circulation 2021; 143:e72.</li>
<li>Vahanian A, Beyersdorf F, Praz F, et al. 2021
		ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J
		2021; ehab395.</li>
</ol></div><div id="graphicVersion">Graphic 134485 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
